Towards trans-diagnostic mechanisms in psychiatry: Neurobehavioral profile of rats with a loss of function point mutation in the dopamine transporter gene

Abstract

The research domain criteria (RDoC) matrix has been developed to reorient psychiatric research towards measurable behavioral dimensions and underlying mechanisms. Here, we used a new genetic rat model with a loss-of-function point mutation in the dopamine transporter (DAT) gene (Slc6a3_N157K) to systematically study the RDoC matrix. First, we examined the impact of the Slc6a3_N157K mutation on monoaminergic signaling. We then performed behavioral tests representing each of the five RDoC domains: negative and positive valence systems, cognitive, social and arousal/regulatory systems. The use of RDoC may be particularly helpful for drug development. We studied the effects of a novel pharmacological approach metabotropic glutamate receptor mGluR2/3 antagonism, in DAT mutants in a comparative way with standard medications. Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission. DAT mutant rats showed deficits in all five RDoC domains. Thus, mutant rats failed to show conditioned fear responses, were anhedonic, were unable to learn stimulus-reward associations, showed impaired cognition and social behavior, and were hyperactive. Hyperactivity in mutant rats was reduced by amphetamine and atomoxetine, which are well-established medications to reduce hyperactivity in humans. The mGluR2/3 antagonist LY341495 also normalized hyperactivity in DAT mutant rats without affecting extracellular dopamine levels. We systematically characterized an altered dopamine system within the context of the RDoC matrix and studied mGluR2/3 antagonism as a new pharmacological strategy to treat mental disorders with underlying subcortical dopaminergic hyperactivity.

The Neurobiology of Eating Disorders

“…Neurobiological research in eating disorders (EDs) holds promise for developing a medical model perspective to reduce stigma and help develop better treatments. 4…”

Alcohol reduces muscle fatigue through atomistic interactions with nicotinic receptors

“…Home-cage activity was monitored by use of an infrared sensor connected to a recording and data storing system E-Motion (Infra-e-motion, Henstedt-Ulzburg, Germany) 66 . Rats were placed in single cages for 3 days and an E-Motion device was placed above each cage (30 cm from the bottom) so that the rat could be detected at any position inside the cage.…”

“…To measure the locomotor activity in a novel environment, an open field apparatus was used 66 . An open field was a dark PVC box of four equal squares (51 × 51 × 50 cm).…”

The role of glutamate receptors in attention‐deficit/hyperactivity disorder: From physiology to disease

“…DAT mutant rats showed impaired cognition and social behavior, and were hyperactive, while the mGluR2/3 antagonist LY341495 normalized hyperactivity in DAT mutant rats without affecting extracellular dopamine levels (Vengeliene et al, ). Hyperactivity phenotype of DAT‐KO mice could be reinforced by blocker of NMDARs and improved by drugs facilitated the glutamatergic synapse transmission (Gainetdinov et al, ).…”

“…In addition, though lacking the dopamine transporter, DAT knockout mice were able to respond to MPH (Gainetdinov et al, ) and their hyperactivity phenotype could be reinforced by blocker of NMDARs and improved by drugs facilitated the glutamatergic synapse transmission (Gainetdinov et al, ). The mGluR2/3 antagonist LY341495 normalized hyperactivity in DAT mutant rats without affecting extracellular dopamine levels (Vengeliene et al, ). AMPARs antagonists, mGluR7 agonist, Group II mGluR agonists, and dopamine D2 receptor antagonist attenuated locomotor hyperactivity and novelty‐induced hyperlocomotion of the GluRs knockout mice (Boerner et al, ; Maksimovic, Aitta‐aho, & Korpi, ; Palucha et al, ; Procaccini et al, , ).…”